Get started
Author

Riitta Korpisaari

Observed name: R. Korpisaari
Observed institution: Docrates Cancer Center
ORCID: 0009-0000-9924-1629
Observed ORCID: 0009-0000-9924-1629
OpenAlex ID: A5007169190
Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al. · Clinical Cancer Research · 39
PDF
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
2023 · Joao Santos, Katriina Peltola, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
2023 · Joao Santos, Inge Svane, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
1579P Fully intravenous split-dose administration of oncolytic adenovirus TILT-123 in advanced solid tumors
2025 · E. Jirovec, D.C.A. Quixabeira, et al. · Annals of Oncology
163P Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
2024 · E. Jirovec, D.C.A. Quixabeira, et al. · Immuno-Oncology Technology
PDF
Figure 2 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
Supplementary Data 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
Table 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
Figure 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
Table 2 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
Table 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
Data from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
Figure 3 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
Figure 4 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
Figure 3 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
1025P Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers
2024 · S.A. Pakola, K. Jalkanen, et al. · Annals of Oncology
711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours – from preclinical testing to phase I clinical trials
2023 · James Clubb, Victor Cervera-Carrascon, et al. · Journal for ImmunoTherapy of Cancer
PDF
739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial
2023 · Santeri A Pakola, Victor Cervera-Carrascon, et al. · Journal for ImmunoTherapy of Cancer
PDF
745 Immune cell profiling of advanced-stage solid tumors patients treated with an oncolytic adenovirus encoding for TNF-a and IL-2 (TILT-123)
2023 · Dafne CA Quixabeira, Santeri A Pakola, et al. · Journal for ImmunoTherapy of Cancer
PDF
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials
2022 · Victor Cervera-Carrascon, Inge Svane, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 20
Citation count: 42
H-index: 2
I10-index: 1
Year
Topic
Type